Background: Chronic lymphoid leukemia (CLL) is the most frequent type of adult leukemia. The Rai andBinet staging systems have been well recognized as standards for assessing the treatment requirements andoverall survival in CLL patients. However, there is a need to seek newer prognostic markers to identify stable orprogressive forms of CLL that will facilitate risk-adapted treatment strategies. Currently a molecular biomarkerZAP-70 has attracted interest as providing prognostic information in CLL patients.
Objective: To determinethe frequency of ZAP-70 positivity in B-CLL patients at disease presentation. Materials and
Methods: FromJanuary 2011 to September 2014, 89 patients were diagnosed to have chronic lymphoid leukemia. Completeblood count was done on an automated analyzer (Cell Dyne, Abott Architect, USA), while immunophenotypingwas conducted for each patient to establish the diagnosis of the disease. ZAP-70 expression was evaluated byflow cytometry. Data were compiled and analyzed by SPSS version 21.
Results: Out of the total of 89 B-CLLpatients, 62 (69.7%) were male and 27 (30.3%) were females with a male to female ratio of 2:1. The mean agewas 57.5±12.1 years. The frequency of ZAP-70 positivity in our B-CLL patients was found to be 13.5%. ZAP-70 positivity was significantly correlated with stage III disease and high absolute lymphocytic count (P<0.05).No correlation of ZAP-70 could be established with age and gender (p>0.05).
Conclusions: The frequency ofZAP-70 in our patients appears low. It is approximately half that in international data. We would recommendto screen all the newly diagnosed patients with CLL for ZAP-70 protein expression for risk stratification, familycounseling and to predict overall survival.